Inspire Medical Systems (NYSE:INSP) Insider Jason Kelly Sells 963 Shares

Inspire Medical Systems, Inc. (NYSE:INSP) insider Jason Kelly sold 963 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $59.55, for a total transaction of $57,346.65. Following the completion of the transaction, the insider owned 18,985 shares in the company, valued at approximately $1,130,556.75. The trade was a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Inspire Medical Systems Stock Down 0.8%

Shares of NYSE INSP opened at $59.25 on Wednesday. The firm’s 50-day moving average price is $48.39 and its two-hundred day moving average price is $53.75. Inspire Medical Systems, Inc. has a 52-week low of $38.91 and a 52-week high of $147.03. The stock has a market capitalization of $1.71 billion, a P/E ratio of 12.83, a P/E/G ratio of 4.54 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.38. The company had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The business’s revenue was down 7.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, equities research analysts expect that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current year.

Institutional Trading of Inspire Medical Systems

A number of institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada raised its holdings in Inspire Medical Systems by 16.0% during the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock worth $5,220,000 after purchasing an additional 4,528 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Inspire Medical Systems in the first quarter worth approximately $524,000. Goldman Sachs Group Inc. boosted its stake in Inspire Medical Systems by 57.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock valued at $8,190,000 after purchasing an additional 18,857 shares in the last quarter. Marshall Wace LLP boosted its stake in Inspire Medical Systems by 3.8% during the 2nd quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock valued at $2,064,000 after purchasing an additional 577 shares in the last quarter. Finally, Jump Financial LLC acquired a new position in shares of Inspire Medical Systems during the 2nd quarter valued at $931,000. 94.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

INSP has been the subject of several recent research reports. Piper Sandler upped their price target on shares of Inspire Medical Systems from $55.00 to $60.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Bank of America cut shares of Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price for the company. in a research report on Friday, May 22nd. Truist Financial restated a “hold” rating and issued a $62.00 price target (up from $54.00) on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Weiss Ratings reiterated a “sell (d)” rating on shares of Inspire Medical Systems in a research report on Monday, August 3rd. Finally, JPMorgan Chase & Co. increased their price objective on Inspire Medical Systems from $54.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $68.00.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.